RP
RPG.F REGENT PACIFIC GRP
- Market cap
- EUR 26.8M
- P/E
- -
- P/B
- 2.06x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is RPG.F undervalued?
Graham numberThe Graham number of REGENT PACIFIC GRP cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
REGENT PACIFIC GRP fundamental analysis
No fundamental analysis for REGENT PACIFIC GRP yet.
REGENT PACIFIC GRP stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About REGENT PACIFIC GRP
Regent Pacific Group Limited, an investment holding company, focuses on healthcare and life sciences sectors in the United States, Europe, and Asia Pacific. The company operates through two segments, Biopharma and Corporate Investment. It is involved in the research, development, manufacturing, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of AI system for the field of biological aging clocks, at the …
Full company profileREGENT PACIFIC GRP financial statements
REGENT PACIFIC GRP annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 3.25M | 114K | 291K | 719K | 363K |
| Gross Profit | -355K | -2.85M | -2.43M | -2.12M | - |
| Operating Income | -28.4M | -30.8M | -28.0M | -4.19M | -4.30M |
| EBITDA | - | -9.56M | -7.72M | -4.33M | -4.33M |
| Net Income | -12.6M | -36.4M | -25.0M | -4.48M | -4.71M |
| EPS | -0.11 | -0.30 | -0.11 | -0.02 | -0.02 |
| Balance Sheet | |||||
| Total Assets | 62.2M | 26.3M | 2.80M | 610K | 571K |
| Total Liabilities | 23.5M | 23.7M | 4.35M | 6.51M | 7.21M |
| Shareholders' Equity | 38.8M | 2.60M | -1.55M | -5.90M | -6.64M |
| Cash & Short-term Investments | 613K | 309K | 2.10M | 100K | 135K |
| Cash Flow | |||||
| Operating Cash Flow | -1.70M | 506K | -3.81M | -4.13M | -4.30M |
| Capital Expenditure | 43.0K | 12.0K | 2.00K | 6.00K | 15.0K |
| Free Cash Flow | -1.75M | 494K | -3.81M | -4.14M | -4.31M |
| Ratios | |||||
| ROE | -32.5% | -1,402.7% | - | - | - |
| ROA | -20.2% | -138.4% | -896.2% | -734.8% | -824.9% |
| Net Profit Margin | -387.2% | -31,953.5% | -8,607.9% | -623.4% | -1,297.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
REGENT PACIFIC GRP dividends
REGENT PACIFIC GRP has not paid dividends in the last 8 fiscal years.
Last stock split: 1:20 on Jun 5, 2023.
Who owns REGENT PACIFIC GRP
- Insiders 68.47%
- Institutions 0.00%
- Public & others 31.54%
- Shares outstanding 292M
- Free float 92.0M
REGENT PACIFIC GRP company profile
- Company name
- REGENT PACIFIC GRP
- Ticker
- RPG.F
- ISIN
- KYG3042R1314
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Capital Markets
- Employees
- 15
- Fiscal year end
- December
- Address
- Henley Building, Central, Hong Kong
- Phone
- 852 2514 6111
- Website
- regentpac.com
About REGENT PACIFIC GRP
Regent Pacific Group Limited, an investment holding company, focuses on healthcare and life sciences sectors in the United States, Europe, and Asia Pacific. The company operates through two segments, Biopharma and Corporate Investment. It is involved in the research, development, manufacturing, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of AI system for the field of biological aging clocks, at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. The company also invests in listed and unlisted corporate entities. In addition, it provides management services. The company was formerly known as Endurance RP Limited and changed its name to Regent Pacific Group Limited in July 2023. Regent Pacific Group Limited was founded in 1991 and is headquartered in Central, Hong Kong.
REGENT PACIFIC GRP management
6- Mr. Jamie Alexander GibsonCEO & Executive Director · born 1966
- Dr. Michael Grant Wyllie BScCo-Founder & Chief Scientific Officer · born 1951
- Mr. Yui Fui WongChief Financial Officer · born 1975
- Mr. Paul Eric Jones BA, MBAInvestment Director · born 1965
- Ms. Mei Yan LuiCompany Secretary · born 1975
- Prof. John Michael Fitzpatrick FC Urol (SA), FRCS, FRCSGlas, FRCSI, MChChairman of Clinical Scientific Advisory Board